Literature DB >> 31266829

DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway.

Vishal Kothari1, Jonathan F Goodwin2, Shuang G Zhao3, Justin M Drake4, Yi Yin5, S Laura Chang3, Joseph R Evans6, Kari Wilder-Romans3, Kristina Gabbara3, Emanuela Dylgjeri2, Jonathan Chou7, Grace Sun3, Scott A Tomlins8,9,10, Rohit Mehra8,9,10, Kristen Hege11, Ellen H Filvaroff11, Edward M Schaeffer12, R Jeffrey Karnes13, David A Quigley14, Dana E Rathkopf15, Housheng H He16,17, Corey Speers3,10, Daniel E Spratt3, Luke A Gilbert18, Alan Ashworth14,14, Arul M Chinnaiyan8,9,10,19, Ganesh V Raj5, Karen E Knudsen20,21,22,23, Felix Y Feng24,7,14,18.   

Abstract

PURPOSE: Protein kinases are known to play a prominent role in oncogenic progression across multiple cancer subtypes, yet their role in prostate cancer progression remains underexplored. The purpose of this study was to identify kinases that drive prostate cancer progression.Experimental Design: To discover kinases that drive prostate cancer progression, we investigated the association between gene expression of all known kinases and long-term clinical outcomes in tumor samples from 545 patients with high-risk disease. We evaluated the impact of genetic and pharmacologic inhibition of the most significant kinase associated with metastatic progression in vitro and in vivo.
RESULTS: DNA-dependent protein kinase (DNAPK) was identified as the most significant kinase associated with metastatic progression in high-risk prostate cancer. Inhibition of DNAPK suppressed the growth of both AR-dependent and AR-independent prostate cancer cells. Gene set enrichment analysis nominated Wnt as the top pathway associated with DNAPK. We found that DNAPK interacts with the Wnt transcription factor LEF1 and is critical for LEF1-mediated transcription.
CONCLUSIONS: Our data show that DNAPK drives prostate cancer progression through transcriptional regulation of Wnt signaling and is an attractive therapeutic target in aggressive prostate cancer. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 31266829      PMCID: PMC6744969          DOI: 10.1158/1078-0432.CCR-18-2387

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  43 in total

1.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data.

Authors:  Rafael A Irizarry; Bridget Hobbs; Francois Collin; Yasmin D Beazer-Barclay; Kristen J Antonellis; Uwe Scherf; Terence P Speed
Journal:  Biostatistics       Date:  2003-04       Impact factor: 5.899

2.  Ku autoantigen is the regulatory component of a template-associated protein kinase that phosphorylates RNA polymerase II.

Authors:  A Dvir; S R Peterson; M W Knuth; H Lu; W S Dynan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

3.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

4.  Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process.

Authors:  Uma R Chandran; Changqing Ma; Rajiv Dhir; Michelle Bisceglia; Maureen Lyons-Weiler; Wenjing Liang; George Michalopoulos; Michael Becich; Federico A Monzon
Journal:  BMC Cancer       Date:  2007-04-12       Impact factor: 4.430

Review 5.  The development of androgen-independent prostate cancer.

Authors:  B J Feldman; D Feldman
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

6.  Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles.

Authors:  Daniel R Rhodes; Shanker Kalyana-Sundaram; Vasudeva Mahavisno; Radhika Varambally; Jianjun Yu; Benjamin B Briggs; Terrence R Barrette; Matthew J Anstet; Colleen Kincead-Beal; Prakash Kulkarni; Sooryanaryana Varambally; Debashis Ghosh; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

7.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

Review 8.  Wnt signalling and its impact on development and cancer.

Authors:  Alexandra Klaus; Walter Birchmeier
Journal:  Nat Rev Cancer       Date:  2008-05       Impact factor: 60.716

9.  Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells.

Authors:  X Yang; M-W Chen; S Terry; F Vacherot; D L Bemis; J Capodice; J Kitajewski; A de la Taille; M C Benson; Y Guo; R Buttyan
Journal:  Oncogene       Date:  2006-02-13       Impact factor: 9.867

10.  Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis.

Authors:  X Li; V Placencio; J M Iturregui; C Uwamariya; A-R Sharif-Afshar; T Koyama; S W Hayward; N A Bhowmick
Journal:  Oncogene       Date:  2008-08-25       Impact factor: 9.867

View more
  5 in total

1.  A Data Science Approach for the Identification of Molecular Signatures of Aggressive Cancers.

Authors:  Adriano Barbosa-Silva; Milena Magalhães; Gilberto Ferreira Da Silva; Fabricio Alves Barbosa Da Silva; Flávia Raquel Gonçalves Carneiro; Nicolas Carels
Journal:  Cancers (Basel)       Date:  2022-05-07       Impact factor: 6.575

Review 2.  Wnt/β-catenin signaling pathway in uterine leiomyoma: role in tumor biology and targeting opportunities.

Authors:  Malak El Sabeh; Subbroto Kumar Saha; Sadia Afrin; Md Soriful Islam; Mostafa A Borahay
Journal:  Mol Cell Biochem       Date:  2021-05-17       Impact factor: 3.842

3.  Long-Read Sequencing Annotation of the Transcriptome in DNA-PK Inactivated Cells.

Authors:  Liwei Song; Mengjun Yu; Renjing Jin; Meng Gu; Ziyu Wang; Dailun Hou; Shaofa Xu; Jinghui Wang; Teng Ma
Journal:  Front Oncol       Date:  2022-08-02       Impact factor: 5.738

Review 4.  Beyond DNA Repair: DNA-PKcs in Tumor Metastasis, Metabolism and Immunity.

Authors:  Haitang Yang; Feng Yao; Thomas M Marti; Ralph A Schmid; Ren-Wang Peng
Journal:  Cancers (Basel)       Date:  2020-11-16       Impact factor: 6.639

Review 5.  Targeting Protein Kinases and Epigenetic Control as Combinatorial Therapy Options for Advanced Prostate Cancer Treatment.

Authors:  Soghra Bagheri; Mahdie Rahban; Fatemeh Bostanian; Fatemeh Esmaeilzadeh; Arash Bagherabadi; Samaneh Zolghadri; Agata Stanek
Journal:  Pharmaceutics       Date:  2022-02-25       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.